The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …

SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some
patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

Infection with SARS-CoV-2 results in clinical outcomes ranging from silent or benign
infection in most individuals to critical pneumonia and death in a few. Genetic studies in …

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3 …

The immense interindividual clinical variability during any infection is a long-standing
enigma. Inborn errors of IFN-γ and IFN-α/β immunity underlying rare infections with weakly …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …